Francisco López-Muñoz
Director
Camilo José Cela University
Spain
Biography
Francisco López-Muñoz is currently working as Professor of Pharmacology, Director of International Doctorate School, Sub-Director of Chair of Genetic Medicine, and Assistant Director of Academic Staff at Camilo José Cela University, and Research Fellow at Hospital Research Institute (Madrid, Spain), and Portucalense Institute of Neuropsychology and Cognitive and Behavioral Neurosciences (INPP), Universidade Portucalense Infante Dom Henrique (Porto, Portugal).
He received his PhD Degree in Medicine at Complutense University in 1993, with a Thesis that won the Doctorate Extraordinary Award, and another PhD Degree in Spanish Language and Literature at University of Alcalá in 2015.
He has supervised 6 PhD theses and has participated in several research projects. Today, he has positive assessment of two six-year research by CNEAI and acts as evaluator of research projects and degrees for several European Agencies (ANECA – Spain, EUFISCDI – Romania, HRB – Ireland). Dr. López-Muñoz is editor/author of 24 books, highlighting its History of Psychopharmacology (4 volumes; NPP Books, 2014), and Neurobiology of Depression (Taylor&Francis, 2012), and 189 chapters of books related to the psychopharmacology. He has published 125 papers on indexed journals and 190 in Spanish and Latin American journals, and has given 28 conferences and 138 communications in scientific meetings. Dr. López-Muñoz is member of several scientific societies (including Collegium International Neuro-Psychopharmacologicum) and editorial boards, and has participated, as visiting Professor, in postgraduate and doctorate courses from different Spanish and international academic centres. . Dr. López-Muñoz has various awards for his research career, and he was appointed in 2015 Academician of the Royal Academy of Doctors.
Research interest:
Biological bases of drug abuse and dual diagnosis, psychotropic drugs interactions, neurobiology of metal disorders, bibliometric techniques applied to mental health-related disciplines and neuropsychopharmacology, combination therapies with antidepressant drugs in resistant depression and with antipsychotics drugs in patients with refractory schizophrenia, and the history of the psychopharmacology and neurosciences.
